Session Information
-
WCLC 2021
2022 World Conference on Lung Cancer
Presentation Date(s):- September 8 - 14, 2021
- Total Presentations: 1107
All times listed are in Mountain Time MDT (UTC-6:00)
PL - Plenary
ES - Education Session
OA - Oral Session
MA - Mini Oral Session
FP - Featured Posters
P - Posters
WS - Workshops
IS - Industry Symposium
MTE - Meet the Expert
BEDG - Brain Exchange Discussion Groups
September 8 Wed
Sep 8 Thursday
September 9 Thu
Sep 9 Friday
September 10 Fri
Sep 10 Saturday
September 11 Sat
Sep 11 Sunday
September 12 Sun
Sep 12 Monday
September 13 Mon
Sep 13 Tuesday
September 14 Tue
Sep 14
-
+
MA03 - Biomarkers for Immunotherapy: Are All Relevant?
- 10:45 - 11:45
- 9/08/2021
- Location: Program Auditorium
- IASLC CME Accredited
- Type: Mini Oral
- Track: Immuno-biology and Novel Immunotherapeutics (Phase I and Translational)
-
+
MA03.02 - TROPION-PanTumor01: Updated Results From the NSCLC Cohort of the Phase 1 Study of Datopotamab Deruxtecan in Solid Tumors
10:50 - 10:55 | Presenter: Edward B Garon
- Abstract
Loading...
-
+
P01 - Early Stage/Localized Disease/Ablative Therapies - Adjuvant Therapy
- 00:00 - 00:00
- 9/08/2021
- Location: ePoster Hall
- Not for CME Credit
- Type: Posters
- Track: Early Stage/Localized Disease/Ablative Therapies
-
+
P01.01 - LIBRETTO-432: A Placebo-Controlled Phase 3 Study of Adjuvant Selpercatinib in Stage IB-IIIA RET Fusion-Positive NSCLC
00:00 - 00:00 | Presenter: Jonathan Goldman
- Abstract
Loading...
-
+
P47 - Novel Therapeutics and Targeted Therapies - Clinical Trial in Progress
- 00:00 - 00:00
- 9/08/2021
- Location: ePoster Hall
- Not for CME Credit
- Type: Posters
- Track: Novel Therapeutics and Targeted Therapies
-
+
P47.05 - A Phase 2 Study of Datopotamab Deruxtecan (Dato-DXd) in Advanced NSCLC With Actionable Genomic Alterations (TROPION-Lung05)
00:00 - 00:00 | Presenter: Melissa L Johnson
- Abstract
Loading... -
+
P47.07 - KEAPSAKE Study of Telaglenastat vs Placebo Plus Standard-of-Care in 1L KEAP1/NRF2-Mutated Non-Squamous Metastatic NSCLC
00:00 - 00:00 | Presenter: David R. Spigel
- Abstract
Loading...
-
+
PL02 - Plenary 2: Presidential Symposium (Japanese, Mandarin, Spanish Translation Available)
- 06:30 - 08:00
- 9/09/2021
- Location: Program Auditorium
- IASLC CME Accredited
- Type: Plenary
- Track: N.A.
- Moderators:David Harpole, Tetsuya Mitsudomi
-
+
PL02.01 - Durvalumab ± Tremelimumab + Chemotherapy as First-line Treatment for mNSCLC: Results from the Phase 3 POSEIDON Study
06:30 - 06:40 | Presenter: Melissa L Johnson
- Abstract
Loading...
-
+
PL02A - Plenary 2: Presidential Symposium (Rebroadcast) (Japanese, Mandarin, Spanish Translation Available)
- 14:30 - 16:00
- 9/09/2021
- Location: Program Auditorium
- IASLC CME Accredited
- Type: Plenary
- Track: N.A.
- Moderators:David Harpole, Tetsuya Mitsudomi
-
+
PL02A.01 - Durvalumab ± Tremelimumab + Chemotherapy as First-line Treatment for mNSCLC: Results from the Phase 3 POSEIDON Study
14:30 - 14:40 | Presenter: Melissa L Johnson
- Abstract
Loading...
-
+
OA15 - Upcoming Molecular Targeted Agents for EGFR exon 20 Insertion and MET Skipping Mutation
- 18:45 - 19:45
- 9/12/2021
- Location: Program Auditorium
- IASLC CME Accredited
- Type: Oral
- Track: Novel Therapeutics and Targeted Therapies
- Moderators:Helena A Yu
-
+
OA15.01 - Mobocertinib in EGFR Exon 20 Insertion–Positive Metastatic NSCLC Patients With Disease Control on Prior EGFR TKI Therapy
18:45 - 18:55 | Presenter: Alexander Spira
- Abstract
Loading...
